Advanced search
1 file | 541.62 KB

Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors

Author
Organization
Abstract
Background: Differences in estrogen (ER) and progesterone (PR) expression between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) could be an underlying reason for the difference in chemo-sensitivity and response to hormonal therapy between ILC and IDC. The aim of this study was to investigate the differences in ER and PR expression levels between postmenopausal patients with hormonal receptor-positive ILC and IDC. Methods: We included all ER and/or PR receptor-positive ILC and IDC, diagnosed between January 2011 and December 2013 from the population-based Netherlands Cancer Registry. A semi-quantitative classification was used to analyze differences in ER/PR expression, which consisted of three ER expression classes: 10-69, 70-89, and >= 90%. Differences in ER and PR expression levels between IDC and ILC were analyzed according to age group, tumor size, axillary nodal status, grade, and HER2 status. Results: In total, 26,339 ER and/or PR-positive breast cancers were included in the study, of which 17% were ILC and 83% IDC. In patients with IDC, 86% of the tumors showed an ER expression level of 90% or more, compared to 84% in those with ILC. In both IDC and ILC a PR expression level of 90% or more was observed in 54% of the tumors. In postmenopausal patients aged 50-69 years no significant differences could be observed in ER and PR expression levels between ILC and IDC. Conclusion: Patients with ER and PR-positive ILC and IDC have similar quantitative ER and PR expression profiles, implicating that ER/PR expression is unlikely to be a confounding factor in studies concerning chemo-sensitivity of ILC and IDC.
Keywords
Invasive lobular carcinoma, Invasive ductal carcinoma, Estrogen receptor, Progesterone receptor, BREAST-CANCER, NEOADJUVANT CHEMOTHERAPY, ADJUVANT CHEMOTHERAPY, ENDOCRINE THERAPY, MANAGEMENT

Downloads

  • Truin2017 Article EstrogenAndProgesteroneRecepto.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 541.62 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Truin, Wilfred, Rudi MH Roumen, Sabine Siesling, Koen Van de Vijver, Vivianne CG Tjan-Heijnen, and Adri C Voogd. 2017. “Estrogen and Progesterone Receptor Expression Levels Do Not Differ Between Lobular and Ductal Carcinoma in Patients with Hormone Receptor-positive Tumors.” Breast Cancer Research and Treatment 164 (1): 133–138.
APA
Truin, W., Roumen, R. M., Siesling, S., Van de Vijver, K., Tjan-Heijnen, V. C., & Voogd, A. C. (2017). Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors. BREAST CANCER RESEARCH AND TREATMENT, 164(1), 133–138.
Vancouver
1.
Truin W, Roumen RM, Siesling S, Van de Vijver K, Tjan-Heijnen VC, Voogd AC. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors. BREAST CANCER RESEARCH AND TREATMENT. 2017;164(1):133–8.
MLA
Truin, Wilfred, Rudi MH Roumen, Sabine Siesling, et al. “Estrogen and Progesterone Receptor Expression Levels Do Not Differ Between Lobular and Ductal Carcinoma in Patients with Hormone Receptor-positive Tumors.” BREAST CANCER RESEARCH AND TREATMENT 164.1 (2017): 133–138. Print.
@article{8577778,
  abstract     = {Background: Differences in estrogen (ER) and progesterone (PR) expression between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) could be an underlying reason for the difference in chemo-sensitivity and response to hormonal therapy between ILC and IDC. The aim of this study was to investigate the differences in ER and PR expression levels between postmenopausal patients with hormonal receptor-positive ILC and IDC. 
Methods: We included all ER and/or PR receptor-positive ILC and IDC, diagnosed between January 2011 and December 2013 from the population-based Netherlands Cancer Registry. A semi-quantitative classification was used to analyze differences in ER/PR expression, which consisted of three ER expression classes: 10-69, 70-89, and >= 90%. Differences in ER and PR expression levels between IDC and ILC were analyzed according to age group, tumor size, axillary nodal status, grade, and HER2 status. 
Results: In total, 26,339 ER and/or PR-positive breast cancers were included in the study, of which 17% were ILC and 83% IDC. In patients with IDC, 86% of the tumors showed an ER expression level of 90% or more, compared to 84% in those with ILC. In both IDC and ILC a PR expression level of 90% or more was observed in 54% of the tumors. In postmenopausal patients aged 50-69 years no significant differences could be observed in ER and PR expression levels between ILC and IDC. 
Conclusion: Patients with ER and PR-positive ILC and IDC have similar quantitative ER and PR expression profiles, implicating that ER/PR expression is unlikely to be a confounding factor in studies concerning chemo-sensitivity of ILC and IDC.},
  author       = {Truin, Wilfred and Roumen, Rudi MH and Siesling, Sabine and Van de Vijver, Koen and Tjan-Heijnen, Vivianne CG and Voogd, Adri C},
  issn         = {0167-6806},
  journal      = {BREAST CANCER RESEARCH AND TREATMENT},
  keywords     = {Invasive lobular carcinoma,Invasive ductal carcinoma,Estrogen receptor,Progesterone receptor,BREAST-CANCER,NEOADJUVANT CHEMOTHERAPY,ADJUVANT CHEMOTHERAPY,ENDOCRINE THERAPY,MANAGEMENT},
  language     = {eng},
  number       = {1},
  pages        = {133--138},
  title        = {Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors},
  url          = {http://dx.doi.org/10.1007/s10549-017-4220-x},
  volume       = {164},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: